fbpx Skip to main content

Approval of Daybue applies to adults and children aged 2 years and older

The U.S. Food and Drug Administration has approved Daybue (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients aged 2 years and older.

Approval was based on results from the phase 3 LAVENDER study in which the efficacy and safety of Daybue was assessed versus placebo in 187 female patients with Rett syndrome (ages 5 to 20 years). Compared with placebo, Daybue was associated with statistically significant improvement for change from baseline in the Rett Syndrome Behaviour Questionnaire total score and the Clinical Global Impression-Improvement scale score at week 12.

The most common side effects were diarrhea (82 percent) and vomiting (29 percent). Daybue is expected to be available in the United States by the end of April 2023.

“As the first FDA-approved drug for the treatment of Rett syndrome, Daybue now offers the potential to make meaningful differences in the lives of patients and their families who have lacked options to treat the diverse and debilitating array of symptoms caused by Rett syndrome,” Steve Davis, CEO of Acadia Pharmaceuticals, said in a statement.

Approval of Daybue was granted to Acadia Pharmaceuticals.

Press Release

More Information

You May Also Like::  Risk Factors for Severe COVID-19 Up in Cancer Survivors

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More